Identification of Serum Proteins Related to Adverse Effects Induced by Docetaxel Infusion from Protein Expression Profiles of Serum Using SELDI ProteinChip System

Background: For the development of quick and easy methods for screening and identifying treatment-responsive proteins, we determined the protein expression profile of the serum after docetaxel infusion using a surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI TOF-M...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2005-03, Vol.25 (2B), p.1197-1203
Main Authors: HEIKE, Yuji, HOSOKAWA, Mami, WAKATABE, Rumi, ARIKUNI, Hisashi, TAKAUE, Yoichi, TAKASHIMA, Shigemitsu, OSUMI, Shozo, FUJII, Daisuke, AOGI, Kenjiro, TAKIGAWA, Nagio, IDA, Mikiko, TAJIRI, Hisao, EGUCHI, Kenji, SHIWA, Mieko
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Biological and medical sciences
Biomarkers - analysis
Blood Proteins - isolation & purification
Breast Neoplasms - drug therapy
Female
Humans
Medical sciences
Protein Array Analysis - methods
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods
Taxoids - adverse effects
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: For the development of quick and easy methods for screening and identifying treatment-responsive proteins, we determined the protein expression profile of the serum after docetaxel infusion using a surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI TOF-MS) system. Materials and Methods: Blood from breast cancer patients was collected before and 4, 8, 24 and 48 hours after docetaxel infusion. The protein expression profile was determined by a SELDI TOF-MS system. The relative expression levels of target proteins were compared during the time-course after docetaxel injection. Results: We identified two representative proteins with molecular weights of 7790 Da and 9285 Da. The 7790 Da protein was high molecular weight kininogen, and the 9285 Da protein was apolipoprotein A-II. These two proteins had similar expression patterns in 5 patients, except one patient who experienced severe, acute, adverse effects. Conclusion: These results suggest that protein expression profiles determined by SELDI TOF-MS represent useful data for the identification of treatment-responsive proteins.
ISSN:0250-7005
1791-7530